-
Polish Archives of Internal Medicine Dec 2019
Topics: Afibrinogenemia; Anticoagulants; Brachial Artery; Female; Humans; Middle Aged; Poland; Recurrence; Thromboembolism; Treatment Outcome
PubMed: 31596272
DOI: 10.20452/pamw.15014 -
BMJ Case Reports Jul 2019Patients with multiple myeloma (MM) are at risk for acquired dysfibrinogenemia resulting in laboratory abnormalities and/or bleeding complications. We describe a...
Patients with multiple myeloma (MM) are at risk for acquired dysfibrinogenemia resulting in laboratory abnormalities and/or bleeding complications. We describe a 63-year-old man who presented with bleeding diathesis in the presence of a low fibrinogen activity level with a normal fibrinogen antigen level. Further studies revealed elevated levels of lambda free light chains, and he was diagnosed with MM. Despite initiating treatment with bortezomib/dexamethasone, he continued to have recurrent bleeds along with hypofibrinogenaemia, prompting a switch to carfilzomib/dexamethasone. The patient responded with improvement in bleeding symptoms, normalisation of fibrinogen activity and a decrease in serum free light chains.
Topics: Afibrinogenemia; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Substitution; Hemorrhage; Humans; Immunoglobulin lambda-Chains; Male; Middle Aged; Multiple Myeloma; Oligopeptides
PubMed: 31320370
DOI: 10.1136/bcr-2019-229312